C-242503040 - Forecasting Submissions

An overview of our requirements is outlined below.  For more information and Proposal submission instructions, refer to the RFP main document. Additional instructions may get published in Bulletins.

Through Health Technology Assessment (HTA), Canada's Drug Agency (CDA-AMC) appraise a drug or technology’s effectiveness against other treatment options and produce a recommendation to inform decisions on public reimbursement. We would like to accurately forecast drug HTA submissions that we are expected to receive from an industry sponsor in the near-term (6-months/1-year), mid-term (3-years) and long-term (5-years).